Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antithrombin III in COVID-19 with Low AT3
NCT04899232Phase 2Terminated
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of antithrombin III in coronavirus disease 2019 (COVID-19). Started Jul 2021; status: terminated.
02
Drugs
antithrombin III
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04899232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899232.